On April 17, 2023 Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis ("NASH"), hepatocellular carcinoma ("HCC"), and other chronic diseases, reported that an abstract highlighting its lead drug candidate, rencofilstat, will be presented by its Chief Scientific Officer, Daren Ure, PhD, at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, which is being held April 15-19, 2023, in Orlando, Florida (Press release, Hepion Pharmaceuticals, APR 17, 2023, View Source [SID1234630155]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Presentation Details
Title: Rencofilstat Exerts a Dominant Role in Synergistic Anti-PD1-Combination Effects in a Fatty Liver Model of Hepatocellular Carcinoma
Authors: Ure D, Leslie J, Haddon L, Variya B, Fu C, Mann J, Mann D
Date: Tuesday, April 18, 2023
Time: 9:00 AM – 12:30 PM ET
A copy of the presentation materials will be accessible on the Company’s website at www.hepionpharma.com under "Publications" in the Pipeline section.